Horizon Discovery and Hisun Pharmaceuticals Partner on Gene-Engineered Bioproduction Cell Line
Horizon Discovery (Horizon) a leading provider of cell line genome engineering products and services, has entered into an agreement with Hisun Pharmaceuticals (Hisun) to optimize Horizon’s newly engineered CHO bioproduction cell line for commercial use. Hisun will be using Horizon’s glutamine synthetase (GS) double knock-out cell line for use in therapeutic antibody manufacturing. Financial terms of the agreement were not disclosed.
Horizon has engineered the CHO cell line using its GENESIS gene editing technology, providing the most precisely engineered GS double knock-out available. The precision afforded by GENESIS results in an optimal final genotype, with complete control over the desired genomic alterations and with no unwanted off-target effects.
GS is a critical enzyme in the metabolism of the amino acid L-glutamine which is often used as a selection marker in the production of recombinant proteins. GS-negative CHO cell lines have proven to be a valuable resource for stringent selection of high producing lines and accelerating the development of cell lines within the Bioproduction industry, offering significant advantages over traditional methods that use an expensive and toxic chemical inhibitor of GS.
Haibin Wang, Senior Vice President, Hisun Pharmaceuticals, said: “Hisun’s competitive edge comes from our focus on pioneering technology and quality product. Horizon’s gene engineering technology is unique in the level of precision it can deliver, and therefore offers great advantages in quality and efficiency for industrial cell line engineering. Partnering with forward-looking leaders in their field, such as Horizon, is a key part of our strategy to provide innovative and quality products to our patients.”
“We are delighted to be working with Hisun on the final development stage for this cell line, the first of several Horizon projects aimed at GMP production of therapeutic proteins,” commented Dr Brian Burke, Business Development Manager at Horizon. “Cell line development has yet to match the gains made in media and feed technology development. Precision gene editing will be a key driver for cell line development, and by selective partnering with leaders like Hisun, Horizon intends to accelerate this process.”
Related News
-
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance